Multiple GPRC5D Agents For Myeloma Raise Questions On Positioning

Johnson & Johnson stands to hit another milestone in multiple myeloma with the likely approval of its bispecific antibody talquetamab as the first drug on the market targeting GPRC5D as well as CD3. But the number of companies developing GPRC5D-targeting therapies – particularly bispecific antibodies and cell therapies – means it is likely to become a crowded marketplace, which is generating discussion among multiple myeloma physicians about how to position and sequence the drugs.

J&J’s Janssen Pharmaceuticals division announced 9 December that it had submitted a biologics license application to the US Food and Drug Administration for talquetamab, based on results from the Phase...